ArticleScientific reports2025
Opportunistic screening of type 2 diabetes with deep metric learning using electronic health records.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Deep learning models leveraging electronic health records (EHR) for opportunistic screening of type 2 diabetes (T2D) can improve current practices by identifying individuals who may need further glycemic testing. Accurate onset prediction and subtyping are crucial for targeted interventions, but existing methods treat the tasks separately, thus limiting clinical utility. In this paper, we introduce a novel deep metric learning (DML) model that unifies both tasks by learning a latent space based on sample similarity. In onset prediction, the DML model predicts the onset of T2D 7 years later with an AUC of 0.754, outperforming logistic regression (AUC 0.706), clinical risk factors (AUC 0.693), and glycemic measures (AUC 0.632). For subtyping, we identify three subtypes with varying prevalences of obesity-related, cardiovascular, and mental health conditions. Additionally, the subtype with fewer comorbidities shows earlier metformin initiation and a greater reduction in HbA1c. We validated these findings using data from 300 U.S. hospitals in the All of Us program (T2D, n = 7567) and the Massachusetts General Brigham Biobank (T2D, n = 3298), demonstrating the transferability of our model and subtypes across cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.